• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

To all those retained from last year.

Anonymous

Guest
time is up!! you will be fired soon. Hope that suprise ride along with your DM wasn't too painful. BELOW expectations on your perfect little record. Your counterpart is next.
 

<